These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now.

UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $28.26 which represents a slight increase of $0.54 or 1.95% from the prior close of $27.72. The stock opened at $27.86 and ...

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To ...

Check the time stamp on this data. Updated AI-Generated Signals for Royalty Pharma Plc (RPRX) available here: RPRX.

The stock market appears to be at a turning point. While major indexes are still hovering near record levels, there ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

Most readers would already be aware that Royalty Pharma's (NASDAQ:RPRX) stock increased significantly by 6.7% over ...

EQS-News: BRAIN Biotech AG / Key word (s): Contract BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator 20.09.2024 / 19:50 CET/CEST ...

The following is a round-up of earnings for London-listed companies, issued on Monday and not separately reported by Alliance News: Alliance Pharma PLC - Chippenham, Wiltshire-based distributor of ...

Pan American Silver's strong balance sheet, diversified portfolio, and potential catalysts make its shares a buy with ...